No baseline genotyping. Fewer in-person medical visits and lab tests. No need for refills. Could the future of HCV treatment take place almost entirely remotely?
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.
IDWeek 2020 provided a perfect opportunity to better understand the modern-day impact of histoplasmosis among Americans living with HIV—and to bone up on the basics.
HIV Clinicians Have Played a Key Role in U.S. COVID-19 Treatment Guidelines. We Spoke With One of Them.
COVID-19 Treatment Guidelines Panel member Arthur Kim, M.D., discusses the guidelines and the experience of treating COVID-19 from an HIV care provider’s perspective.
W. David Hardy, M.D., discusses the takeaway messages for HIV care providers after a recent research paper found that a third of all people living with HIV reported never discussing U=U with their provider.
Scout, Ph.D., the head of the National LGBT Cancer Network, lays out the current state of the interplay between nicotine, cancer, HIV, and people who are LGBTQ.
Infectious-diseases researcher David Wohl, M.D., talks about a major COVID-19 treatment trial in the works—and how it relates to our efforts against HIV.
With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues
The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.
An interview with Andrew Hill, Ph.D., about his research presented at AIDS 2020.